Fewer, larger, more selective: what the first half of 2026 tells us about where private capital is going in MedTech, and how investors should think about carve-outs, take-privates and the categories that are attracting the biggest cheques. The headline number for MedTech M&A in 2026 is striking. In the first half of the year, deal value was roughly 160% higher than the same period in 2025. The more interesting number sits beside it: deal count rose by just 5%. Average deal v